New protocol aims to start lifesaving care for kids with sepsis en route to hospital
NCT ID NCT01293500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a standardized, goal-directed treatment plan given during ambulance transport could improve outcomes for children with Systemic Inflammatory Response Syndrome (SIRS), a severe inflammatory condition. Researchers planned to compare outcomes before and after implementing the protocol in 230 children. The trial was terminated early, so its findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Goal-directed therapeutic protocol (a standardized care plan) and NIRS monitoring
- What this could lead to
- If successful, this approach could improve survival and reduce hospital stays for critically ill children with SIRS by starting treatment earlier during transport.
- What could go wrong
- The trial was terminated, so results are limited. It was also a small, single-center study comparing time periods, not a randomized test, making it hard to draw firm conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC INFLAMMATORY RESPONSE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New rapid test could speed up sepsis diagnosis in ER
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV
- AI could help heart surgery patients get the right Anti-Inflammatory drug
- New drug shows promise for dangerous pancreatitis complication
- New malaria drug put to the test in human trial
- Scientists hunt for leaky vessel clues in ICU patients